Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice - Episode 11

Imetelstat and IMerge Trial Review

November 4, 2024

James K. McCloskey, MD, John Theurer Cancer Center, Thomas W. LeBlanc, MD, MA

Panelists discuss how imetelstat, a telomerase inhibitor recently approved by the FDA on June 6, 2024, works and its efficacy as demonstrated in the IMerge trial, while highlighting key adverse events that community oncologists should be vigilant about when considering this treatment for patients with lower-risk MDS.

EP. 1: Understanding Myelodysplastic Syndromes (MDS): Diagnosis, Classification, and Risk Assessment

EP. 2: Navigating the Heterogeneity of LR-MDS: Importance of Molecular Testing & Risk Stratifying

EP. 3: Clinical Scenario 1: 76-Year-Old Man With Newly Diagnosed MDS With Symptomatic Anemia, RS Positive

EP. 4: Tailoring Treatment for LR-MDS: Patient Factors, Treatment Goals, and Patient Outcomes

EP. 5: First-Line Luspatercept in LR-MDS: A Deep Dive Into the COMMANDS Trial and Clinical Implications in the Real-Life Practice Setting

EP. 6: Managing Luspatercept Therapy: Dosing, Adverse Effects, and Monitoring

EP. 7: Second-Line LR- MDS Setting: Treatment Options and Considerations

EP. 8: Patient Profile: 66-Year-Old Woman with Newly Diagnosed LR-MDS, RS Negative

EP. 9: Luspatercept Role in the RS-Negative Population and Expert Perspectives on the Role of EPO Levels

EP. 10: First-Line ESA vs Luspatercept in LR-MDS: Choosing the Most Appropriate Treatment Option for Each Individual Patient

Now Viewing

EP. 11: Imetelstat and IMerge Trial Review

EP. 12: Looking Ahead in LR-MDS: Future Agents and/or Combination Strategies

Video content above is prompted by the following:

Please review imetelstat, including mechanism of action and FDA approval (imetelstat, June 6, 2024).
IMerge trial (Platzbecker U, et al. Lancet. 2024;403(10423):249-260.)
What are some key adverse events community oncologists should be aware of with imetelstat?